Deven Choksey backs Sun Pharma, Cipla and sees IT upside
In short
Deven Choksey said he likes Sun Pharma and Cipla for fresh buying. He also remains positive on Indian IT companies because of rising AI-related order inflows.
He told investors to wait for corrections before buying Divi's Labs, Laurus Labs, Titan and Kalyan Jewellers. The advice was about where to buy, not a change in company results.
What the reporting says
Deven Choksey said he prefers fresh buying in Sun Pharma and Cipla while staying positive on Indian IT companies. He said the IT view is supported by growing AI-related order inflows. He also advised waiting for corrections in Divi's Labs, Laurus Labs, Titan and Kalyan Jewellers before buying.
Why it matters
Deven Choksey, Managing Director at DRChoksey Finserv, recommended fresh buying in Sun Pharma and Cipla and stayed constructive on Indian IT companies. He linked the IT view to growing AI-related order inflows. At the same time, he said investors should wait for corrections in Divi's Labs, Laurus Labs, Titan and Kalyan Jewellers before buying, making this a sector and stock-selection call.